期刊文献+

胺碘酮联合厄贝沙坦治疗阵发性房颤疗效观察 被引量:14

Therapeutic effect of irbesartan combined with aminodarone in patients with paroxysmal atrial fibrillation
下载PDF
导出
摘要 目的观察胺碘酮联合厄贝沙坦对阵发性房颤的疗效。方法将该科52例诊断为阵发性房颤的患者随机分为治疗组(26例)和对照组(26例)。对照组给予胺碘酮治疗,治疗组在胺碘酮的基础上加用厄贝沙坦联合治疗,观察两组患者1年内房颤复发、转为持续性房颤的发生情况。结果治疗组能够很好的维持窦性心律,1年内房颤复发及转为持续性房颤率明显低于对照组,差异具有统计学意义(P<0.05)。结论胺碘酮联合厄贝沙坦对阵发性房颤具有显著效果,不良反应少,值得临床推广。 Objective To study the therapeutic effect of irbesartan combined with amiodarone in patients with paroxysmal atrial fibrillation(PAF).Methods A total of 52 PAF patients diagnosed by our department were divided into therapeutic group(n=26) and control group(n=26).Both groups received amiodarone,and the therapeutic group received irbesartan additionally.All patients were followed up for 1 year.Changes of recurrence rate of atrial fibrillation and aggravated into persistent atrial fibrillation before and after treatment were observed and compared between the two groups.Results Compared with the control group,there was significant decrease in recurrence rate of atrial fibrillation and aggravated into persistent atrial fibrillation in therapeutic group,P0.05.Conclusion With few adverse effect,irbesartan combined with amiodarone was effective in patients with PAF,which deserved generalization.
作者 王用 邢玉龙
出处 《安徽医药》 CAS 2013年第3期492-493,共2页 Anhui Medical and Pharmaceutical Journal
关键词 胺碘酮 厄贝沙坦 阵发性房颤 aminodarone irbesartan paroxysmal atrial fibrillation
  • 相关文献

参考文献11

二级参考文献75

共引文献83

同被引文献103

  • 1刘英明,朱智明,曹毅,李贤峰,高连如,杨晔,卢才义,王士雯.阻断肾素-血管紧张素系统对高血压患者心房颤动发生危险的影响[J].中国心脏起搏与心电生理杂志,2005,19(4):264-266. 被引量:22
  • 2张克宁,黄申申,李捷,汤玉凤.胺碘酮治疗高血压病伴阵发性房颤的疗效观察[J].中国药师,2005,8(12):1026-1027. 被引量:1
  • 3杜鑫,万征,黄灿亮.高血压合并心房颤动的研究进展[J].中华心律失常学杂志,2006,10(1):73-75. 被引量:10
  • 4陈灏珠,林果为.实用内科学[M].第13版.北京:人民卫生出版社,2009:2005-2011.
  • 5李岗.中西医结合治疗冠心病心绞痛临床研究[J].健康必读(下旬刊),2013,12(7):393.
  • 6Fogari R,Mugellini A,Zoppi A,et al.Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation[J].J Cardiovasc Pharmacol Ther,2012,17(1):34-43.
  • 7Chiang CE,Goethals M,O'Neill JO,et al.Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey:Insights from Realise AF[J].Europace,2013,15(12):1733-1740.
  • 8Loseto G,Canaris D,Mele G,et al.Paroxysmal atrial fibrillation caused by hypokalemia in a healthy donor who underwent PBSC apheresis[J].Bone Marrow Transplant,2013,48(1):155-156.
  • 9Mohebbi M,Ghassemian H.Predicting termination of paroxysmalatrial fibrillation using empirical mode decomposition of the atrialactivity and statistical features of the heart rate variability[J].Medical and Biological Engineering and Computing: Journalof the International Federation for Medical and BiologicalEngineering,2014,52 ( 5): 415-427.
  • 10Ciaccio EJ, Biviano AB, Garan H,et al.The dominantmorphology of fractionated atrial electrograms hasgreater temporal stability in persistent as compared withparoxysmal atrial fibrillation[J].Computers in Biology andMedicine,2013,43 ( 12): 2127-2135.

引证文献14

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部